Compare ASM & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASM | URGN |
|---|---|---|
| Founded | 1968 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.7M | 1.1B |
| IPO Year | N/A | 2017 |
| Metric | ASM | URGN |
|---|---|---|
| Price | $6.23 | $23.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $5.27 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 5.3M | 706.1K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 476.57 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | $86,065,000.00 | ★ $96,516,000.00 |
| Revenue This Year | $38.58 | $27.96 |
| Revenue Next Year | $39.81 | $123.20 |
| P/E Ratio | $47.58 | ★ N/A |
| Revenue Growth | ★ 58.42 | 8.00 |
| 52 Week Low | $0.88 | $3.42 |
| 52 Week High | $6.98 | $30.00 |
| Indicator | ASM | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 50.73 |
| Support Level | $5.73 | $20.99 |
| Resistance Level | $6.48 | $23.81 |
| Average True Range (ATR) | 0.38 | 1.18 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 38.65 | 70.16 |
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.